Dopamine agonist resistant prolactinomas: any alternative medical treatment?
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1573-7403
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Dopamine agonist resistant prolactinomas: any alternative medical treatment? ; volume:23 ; number:1 ; day:14 ; month:9 ; year:2019 ; pages:27-37 ; date:2.2020
Pituitary ; 23, Heft 1 (14.9.2019), 27-37, 2.2020
- Urheber
-
Souteiro, P.
Karavitaki, N.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s11102-019-00987-3
- URN
-
urn:nbn:de:101:1-2020041815185931120634
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 11:02 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Souteiro, P.
- Karavitaki, N.
- SpringerLink (Online service)
Ähnliche Objekte (12)
MicroRNAs in Dopamine Agonist-Resistant Prolactinoma
Treatment Strategies for Dopamine Agonist-Resistant and Aggressive Prolactinomas: A Comprehensive Analysis of the Literature
The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas
Predictors of dopamine agonist resistance in prolactinoma patients
Successful treatment of dopamine dysregulation syndrome with dopamine D2 partial agonist antipsychotic drug
Leukoderma Induced by Rotigotine Patch, a Transdermal Dopamine Agonist
Peripheral biomarkers of cognitive response to dopamine receptor agonist treatment
Discriminative learning occasioned by the administration of a dopamine agonist
Clinically Combating Reward Deficiency Syndrome (RDS) with Dopamine Agonist Therapy as a Paradigm Shift: Dopamine for Dinner?
Bacteriophobic Zwitterionic/Dopamine Coatings for Medical Elastomers
Predictors of neuropsychiatric side effects of dopamine-agonist therapy in patients with prolactinomas
Predictors of neuropsychiatric side effects of dopamine-agonist therapy in patients with prolactinomas
MicroRNAs in Dopamine Agonist-Resistant Prolactinoma
Treatment Strategies for Dopamine Agonist-Resistant and Aggressive Prolactinomas: A Comprehensive Analysis of the Literature
The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas
Predictors of dopamine agonist resistance in prolactinoma patients
Successful treatment of dopamine dysregulation syndrome with dopamine D2 partial agonist antipsychotic drug
Leukoderma Induced by Rotigotine Patch, a Transdermal Dopamine Agonist
Peripheral biomarkers of cognitive response to dopamine receptor agonist treatment
Discriminative learning occasioned by the administration of a dopamine agonist
Clinically Combating Reward Deficiency Syndrome (RDS) with Dopamine Agonist Therapy as a Paradigm Shift: Dopamine for Dinner?
Bacteriophobic Zwitterionic/Dopamine Coatings for Medical Elastomers
Predictors of neuropsychiatric side effects of dopamine-agonist therapy in patients with prolactinomas
Predictors of neuropsychiatric side effects of dopamine-agonist therapy in patients with prolactinomas
MicroRNAs in Dopamine Agonist-Resistant Prolactinoma
Treatment Strategies for Dopamine Agonist-Resistant and Aggressive Prolactinomas: A Comprehensive Analysis of the Literature
The role of MAPK11/12/13/14 (p38 MAPK) protein in dopamine agonist-resistant prolactinomas
Predictors of dopamine agonist resistance in prolactinoma patients
Successful treatment of dopamine dysregulation syndrome with dopamine D2 partial agonist antipsychotic drug
Leukoderma Induced by Rotigotine Patch, a Transdermal Dopamine Agonist
Peripheral biomarkers of cognitive response to dopamine receptor agonist treatment
Discriminative learning occasioned by the administration of a dopamine agonist
Clinically Combating Reward Deficiency Syndrome (RDS) with Dopamine Agonist Therapy as a Paradigm Shift: Dopamine for Dinner?
Bacteriophobic Zwitterionic/Dopamine Coatings for Medical Elastomers
Predictors of neuropsychiatric side effects of dopamine-agonist therapy in patients with prolactinomas